紐約醫師稱治療新冠肺炎患者達成「零死亡、零住院、零插管」成效

一名紐約醫師澤倫柯(Zev Zelenko)在一封公開信中,向美國總統川普和全球醫療專家報告他對新冠肺炎的治療成果,他聲稱初步達成「零死亡、零住院和零插管」。

澤倫柯醫師說,他採用雞尾酒療法治療新冠肺炎600名確診患者,達成零死亡、零住院和零插管的治療效果。他說,除了有大約10%的患者出現暫時性噁心和腹瀉外,沒有出現任何副作用。不過,儘管如此,他強調,從事任何療法前,務必諮詢醫師。

一個US Liberty Wire網站刊出澤倫柯的公開信內容。

澤倫柯在信中指出,過去16年他一直照顧基里亞斯喬爾社區,大約75%的成年人,這是個由近3萬5000人組成的社區。

截至目前,他的團隊已對這個社區的約200名居民採檢,其中65%的成年人對病毒呈陽性反應。如果以此推斷,整個社區有2萬多人受感染。

由於情況緊急,他針對到院前醫療照護擬定的治療方案,成效良好。方案內容包括無論年齡大小,呼吸急促的患者都需接受治療;高風險類別患者即使症狀輕微,也需接受治療;年輕、健康和低風險患者出現症狀,不必立即接受治療。除非轉成嚴重症狀。

他說自己的門診治療方案如下:

1.羥氯奎寧200毫克,每天兩次,連續5天。

2.阿奇黴素500毫克,每天一次,連續5天。

3.硫酸鋅220毫克,每天一次,連續5天。

澤羅柯說,從26號以來他的團隊,為基里亞斯喬爾約350名患者和紐約其他地區的150名患者提供治療,初步達成零死亡、零住院和零插管。此外,除了有約10%的患者出現暫時性噁心和腹瀉外,沒聽到有任何副作用。

以下是公開信全文。

My name is Dr. Zev Zelenko and I practice medicine in Monroe, NY. For the last 16 years, I have cared for approximately 75% of the adult population of Kiryas Joel, which is a very close knit community of approximately 35,000 people in which the infection spread rapidly and unchecked prior to the imposition of social distancing.

As of today my team has tested approximately 200 people from this community for Covid-19, and 65% of the results have been positive. If extrapolated to the entire community, that means more than 20,000 people are infected at the present time. Of this group, I estimate that there are 1500 patients who are in the high-risk category (i.e. >60, immunocompromised, comorbidities, etc).

Given the urgency of the situation, I developed the following treatment protocol in the pre-hospital setting and have seen only positive results:

Any patient with shortness of breath regardless of age is treated.

Any patient in the high-risk category even with just mild symptoms is treated.

Young, healthy and low risk patients even with symptoms are not treated (unless their circumstances change and they fall into category 1 or 2).

My out-patient treatment regimen is as follows:

Hydroxychloroquine 200mg twice a day for 5 days

Azithromycin 500mg once a day for 5 days

Zinc sulfate 220mg once a day for 5 days

The rationale for my treatment plan is as follows. I combined the data available from China and South Korea with the recent study published from France (sites available on request). We know that hydroxychloroquine helps Zinc enter the cell. We know that Zinc slows viral replication within the cell. Regarding the use of azithromycin, I postulate it prevents secondary bacterial infections. These three drugs are well known and usually well tolerated, hence the risk to the patient is low.

Since last Thursday, my team has treated approximately 350 patients in Kiryas Joel and another 150 patients in other areas of New York with the above regimen.

Of this group and the information provided to me by affiliated medical teams, we have had ZERO deaths, ZERO hospitalizations, and ZERO intubations. In addition, I have not heard of any negative side effects other than approximately 10% of patients with temporary nausea and diarrhea.

In sum, my urgent recommendation is to initiate treatment in the outpatient setting as soon as possible in accordance with the above. Based on my direct experience, it prevents acute respiratory distress syndrome (ARDS), prevents the need for hospitalization and saves lives.

With much respect,

Dr. Zev Zelenko

(圖取自網站)

--------------------------------------------------------------------------------

.{EDITED:1}

.{ORIGINAL-TIME:03-30-20 22:41:08}

Comment 0